Biblio Discovery — Demo Discovery Service

12 results for "Franz, David Neal"

Showing 1–12 · 1.01 seconds · RSS

  1. Journal Article Full text

    Everolimus in the treatment of subependymal giant cell astrocytomas, angiomyolipomas, and pulmonary and skin lesions associated with tuberous sclerosis complex

    Franz, David Neal

    Biologics · 2013 · English · PubMed Central

    Tuberous sclerosis complex (TSC) is an autosomal dominant genetic disorder caused by inactivating mutations in either the TSC1 or TSC2 genes. It is characterized by the development of multiple, benign tumors in several organs throughout the body. Lesions occur in the brain, kidneys, heart, liver…

  2. Journal Article Full text

    Changing the outcome in genetic brain disorders

    Franz, David Neal

    Dev Med Child Neurol · 2022 · English · PubMed Central

    This commentary is on the original articles by Wang et al. and Zhang et al. on pages 1230–1236 and 1237–1245 of this issue.

  3. Journal Article Full text

    Profile of everolimus in the treatment of tuberous sclerosis complex: an evidence-based review of its place in therapy

    Capal, Jamie K; Franz, David Neal

    Neuropsychiatr Dis Treat · 2016 · English · PubMed Central

    Tuberous sclerosis complex (TSC) is a relatively rare genetic disorder, affecting one in 6,000 births. Mammalian target of rapamycin (mTOR) inhibitors, such as everolimus, which have been previously used to prevent solid organ transplant rejection, augment anticancer treatment regimens, and prevent…

  4. Journal Article Full text

    Everolimus long-term safety and efficacy in subependymal giant cell astrocytoma

    Krueger, Darcy A.; Care, Marguerite M.; Agricola, Karen et al.

    Neurology · 2013 · English · PubMed Central

    OBJECTIVE: To report long-term efficacy and safety data for everolimus for the treatment of subependymal giant cell astrocytoma (SEGA) in patients with tuberous sclerosis complex (TSC). METHODS: This was an open-label extension phase of a prospective, phase 1–2 trial (NCT00411619) in patients ≥3…

  5. Journal Article Full text

    A systematic review on the burden of illness in individuals with tuberous sclerosis complex (TSC)

    Zöllner, Johann Philipp; Franz, David Neal; Hertzberg, Christoph et al.

    Orphanet J Rare Dis · 2020 · English · PubMed Central

    OBJECTIVE: This review will summarize current knowledge on the burden of illness (BOI) in tuberous sclerosis complex (TSC), a multisystem genetic disorder manifesting with hamartomas throughout the body, including mainly the kidneys, brain, skin, eyes, heart, and lungs. METHODS: We performed a…

  6. Journal Article Full text

    Long-term treatment of epilepsy with everolimus in tuberous sclerosis

    Krueger, Darcy A.; Wilfong, Angus A.; Mays, Maxwell et al.

    Neurology · 2016 · English · PubMed Central

    OBJECTIVE: To evaluate the long-term benefit and safety of everolimus for the treatment of medically refractory epilepsy in patients with tuberous sclerosis complex (TSC). METHODS: Everolimus was titrated over 4 weeks and continued an additional 8 weeks in a prospective, open-label, phase I/II…

  7. Journal Article Full text

    Longitudinal effects of everolimus on white matter diffusion in Tuberous Sclerosis Complex

    Peters, Jurriaan M.; Prohl, Anna; Kapur, Kush et al.

    Pediatr Neurol · 2018 · English · PubMed Central

    OBJECTIVE: To study longitudinal effects of everolimus, an inhibitor of the mechanistic target of rapamycin (mTOR), on callosal white matter diffusion tensor imaging (DTI) in patients with tuberous sclerosis complex (TSC). METHODS: Serial imaging data spanning 9 years was used from the open label…

  8. Journal Article Full text

    Frequency, Progression, and Current Management: Report of 16 New Cases of Nonfunctional Pancreatic Neuroendocrine Tumors in Tuberous Sclerosis Complex and Comparison With Previous Reports

    Mowrey, Kate; Northrup, Hope; Rougeau, Peyton et al.

    Front Neurol · 2021 · English · PubMed Central

    Background: Tuberous sclerosis complex (TSC) is a genetic condition that causes benign tumors to grow in multiple organ systems. Nonfunctional pancreatic neuroendocrine tumors (PNETs) are a rare clinical feature of TSC with no specific guidelines outlined for clinical management at this time. Our…

  9. Journal Article Full text

    Similar Trends in Serum VEGF-D Levels and Kidney Angiomyolipoma Responses with Longer Duration Sirolimus Treatment in Adults with Tuberous Sclerosis

    Malinowska, Izabela A.; Lee, Nancy; Kumar, Vidhya et al.

    PLoS One · 2013 · English · PubMed Central

    CONTEXT: We have previously shown that serum VEGF-D is elevated at baseline, correlates with kidney angiomyolipoma size at baseline and 12 months, and decreases with sirolimus treatment in adults with tuberous sclerosis complex (TSC). To further investigate the utility of serum VEGF-D for longer…

  10. Journal Article Full text

    Mutational Analysis in a Cohort of 224 Tuberous Sclerosis Patients Indicates Increased Severity of TSC2, Compared with TSC1, Disease in Multiple Organs

    Dabora, Sandra L.; Jozwiak, Sergiusz; Franz, David Neal et al.

    Am J Hum Genet · 2000 · English · PubMed Central

    Tuberous sclerosis (TSC) is a relatively common hamartoma syndrome caused by mutations in either of two genes, TSC1 and TSC2. Here we report comprehensive mutation analysis in 224 index patients with TSC and correlate mutation findings with clinical features. Denaturing high-performance liquid…

  11. Journal Article Full text

    Multicenter Phase 2 Trial of Sirolimus for Tuberous Sclerosis: Kidney Angiomyolipomas and Other Tumors Regress and VEGF- D Levels Decrease

    Dabora, Sandra L.; Franz, David Neal; Ashwal, Stephen et al.

    PLoS One · 2011 · English · PubMed Central

    BACKGROUND: Tuberous sclerosis (TSC) related tumors are characterized by constitutively activated mTOR signaling due to mutations in TSC1 or TSC2. METHODS: We completed a phase 2 multicenter trial to evaluate the efficacy and tolerability of the mTOR inhibitor, sirolimus, for the treatment of…

  12. Journal Article Full text

    Preventative treatment of tuberous sclerosis complex with sirolimus: Phase I safety and efficacy results

    Capal, Jamie K.; Ritter, David M.; Franz, David Neal et al.

    Ann Child Neurol Soc · 2024 · English · PubMed Central

    OBJECTIVE: Tuberous sclerosis complex (TSC) results from overactivity of the mechanistic target of rapamycin (mTOR). Sirolimus and everolimus are mTOR inhibitors that treat most facets of TSC but are understudied in infants. We sought to understand the safety and potential efficacy of preventative…